首页> 外文期刊>American Journal of Pharmacological Sciences >Docking Analysis of 07 Anti-HCV Drugs with COVID-19 Main Protease PDB ID 6LU7
【24h】

Docking Analysis of 07 Anti-HCV Drugs with COVID-19 Main Protease PDB ID 6LU7

机译:07抗HCV药物对接分析Covid-19主要蛋白酶PDB ID 6LU7

获取原文
           

摘要

07 anti-HCV drugs have been processed and observed by docking analysis for understanding the binding patteren of drugs with COVID-19 main protease PDB ID: 6LU7 for any possibilities of protease inhibition. For docking analysis PyRx- Python Prescription 0.8 was used. This analysis reveals that the essential amino acids involved in binding of anti-HCV drugs to COVID-19 main protease PDB ID: 6LU7 are Threonine (THR), Cysteine (CYS), Histidine (HIS), Methionine (MET) and Proline (PRO). After docking analysis it was observed that Ledipasvir may be act as COVID-19 main protease inhibitor despite of being anti-HCV and may further be used in the treatment of COVID-19 infection after having proper clinical proofs.
机译:通过对接分析处理和观察07抗HCV药物,以了解药物与Covid-19主要蛋白酶PDB ID:6LU7的任何可能性抑制药物的抑制剂的结合分析。对于对接分析,使用Pyrx-Python处方0.8。该分析表明,参与抗HCV药物结合到Covid-19主要蛋白酶PDB ID:6Lu7的必需氨基酸:6Lu7是苏氨酸(Thr),半胱氨酸(Cys),组氨酸(HI),蛋氨酸(Met)和ProLine(Pro )。在对接分析之后,观察到,尽管抗HCV尽管是Covid-19主要蛋白酶抑制剂,但在具有适当的临床证据后,可以进一步用于治疗Covid-19感染的Covid-19主要蛋白酶抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号